John P. Neoptolemos, MD, PhD, on Pancreatic Ductal Adenocarcinoma: Results of the ESPAC-4 Trial
2016 ASCO Annual MeetingJohn P. Neoptolemos, MD, PhD, of the University of Liverpool, discusses findings from this international phase III study of adjuvant combination chemotherapy: gemcitabine and capecitabine vs monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma (Abstract LBA4006).
Related Videos
Eduardo L. Cazap, MD, PhD, and Mary Gospodarowicz, MD, on The South American Perspective of Cancer Research
Eduardo L. Cazap, MD, PhD, of the Latinamerican & Caribbean Society of Medical Oncology, and Mary Gospodarowicz, MD, of the Princess Margaret Hospital, discuss on...
Helen MacKay, MD, and Ursula A. Matulonis, MD, on Epithelial Ovarian Cancer: Results From the OV21-PETROC Trial
Helen MacKay, MD, of the Sunnybrook Odette Cancer Centre, and Ursula A. Matulonis, MD, of Dana-Farber Cancer Institute, discuss findings from this phase ...
Arjun Vasant Balar, MD, on Urothelial Carcinoma: Analysis of the IMvigor210 Cohort 1
Arjun Vasant Balar, MD, of the Perlmutter Cancer Center at NYU Langone Medical Center, discusses findings on atezolizumab as first-line therapy in cisplatin-ineligible locally advance...
Anthony J. Olszanski, RPh, MD, and Caroline Robert, MD, PhD, on Results From the KEYNOTE-001 Melanoma Trial
Anthony J. Olszanski, RPh, MD, of Fox Chase Cancer Center, and Caroline Robert, MD, PhD, of Gustave Roussy and Paris-Sud University, discuss study findings on pembrol...
Sagar Lonial, MD, and Andrew Zelenetz, MD, PhD, on MCL, DLBCL, CLL: How Much Rituximab Is Enough?
Sagar Lonial, MD, of Emory University School of Medicine, and Andrew D. Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, discuss newly reported findings ...
